Pre-made Lumiliximab benchmark antibody ( Whole mAb, anti-FCER2/CD23 therapeutic antibody, Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lumiliximab biosimilar, Whole mAb, Anti-FCER2/CD23 Antibody: Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.
| Products Name (INN Index) | Pre-Made Lumiliximab biosimilar, Whole mAb, Anti-FCER2/CD23 Antibody: Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF therapeutic antibody |
|---|---|
| INN Name | Lumiliximab |
| Target | FCER2 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 3fzu:HL:CD |
| 95-98% SI Structure | None |
| Year Proposed | 2004 |
| Year Recommended | 2004 |
| Companies | Biogen Idec |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Allergic asthma,Allergic rhinitis,Chronic lymphocytic leukaemia |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FCER2 |
| Package |
